These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33374879)

  • 1. RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients.
    Aguado C; Giménez-Capitán A; Román R; Rodríguez S; Jordana-Ariza N; Aguilar A; Cabrera-Gálvez C; Rivas-Corredor C; Lianes P; Viteri S; Moya I; Molina-Vila MA
    Diagnostics (Basel); 2020 Dec; 11(1):. PubMed ID: 33374879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High feasibility of cytological specimens for detection of
    Zhang L; Wang Y; Zhao C; Shi J; Zhao S; Liu X; Jia Y; Zhu T; Jiang T; Li X; Zhou C
    Onco Targets Ther; 2019; 12():3305-3311. PubMed ID: 31118681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous analysis of
    Novaes LAC; Sussuchi da Silva L; De Marchi P; Cavagna RO; de Paula FE; Zanon MF; Evangelista AF; Albino da Silva EC; Duval da Silva V; Leal LF; Reis RM
    Transl Lung Cancer Res; 2021 Jan; 10(1):292-303. PubMed ID: 33569313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
    Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
    Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
    Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
    Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR.
    Wang Y; Liu Y; Zhao C; Li X; Wu C; Hou L; Zhang S; Jiang T; Chen X; Su C; Gao G; Li W; Wu F; Li A; Ren S; Zhou C; Zhang J
    Lung Cancer; 2016 Apr; 94():28-34. PubMed ID: 26973203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a high-throughput and sensitive assay of fusion genes in lung cancer by array-based MALDI-TOFMS.
    Wu HT; Li K; Wang G; Yang XX; Zhu A; Xu XP; Li M; Wu YS; Liu TC
    RSC Adv; 2018 Aug; 8(49):27935-27945. PubMed ID: 35548167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical utility of real-time fluorescent PCR for combined detection of anaplastic lymphoma kinase and c-ros oncogene 1 receptor tyrosine kinase in non-small cell lung cancer].
    Bai DY; Zhang HP; Zhong S; Suo WH; Gao DH; Ding Y; Tu JH
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):898-903. PubMed ID: 27998465
    [No Abstract]   [Full Text] [Related]  

  • 17. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
    Wijesinghe P; Bepler G; Bollig-Fischer A
    J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
    Sunami K; Furuta K; Tsuta K; Sasada S; Izumo T; Nakaoku T; Shimada Y; Saito M; Nokihara H; Watanabe S; Ohe Y; Kohno T
    J Thorac Oncol; 2016 Feb; 11(2):203-12. PubMed ID: 26845116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.